Kornimate/medical-research-clean huggingface dataset:
perineal consequences of twin pregnancies according to mode of delivery

Conditions: Pregnancy, Multiple

Summary: this is an ancillary study to the "jumoda" (national prospective and comparative study on the mode of delivery of twins) study: please see nct01987063. the main objective of this study is to investigate the role of the mode of delivery (vaginal versus cesarean) as a risk factor for the occurrence of urinary incontinence at 3 months post-delivery in primiparous women delivering twins after 34 weeks of pregnancy.

the secondary objectives of this study are to compare the following elements between primiparous mothers giving birth to twins vaginally versus by caesarean section after 34 weeks of pregnancy (comparisons will be made at 3 months ant at 12 months post-partum): a. diagnosis, type and severity of urinary incontinence via the iciq-ui questionnaire b. urinary, anorectal and perineal symptoms via the pfdi-20 questionnaire c. quality of life related to urinary, anorectal and pelvic floor symptoms via the pfiq-7 questionnaire d. sexuality via the pisq-12 questionnaire e. general quality of life via the sf-12 questionnaire

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 12 months of follow-up following delivery * the patient was included in the jumoda study * primiparous * birth of 2 live children after 34 weeks of pregnancy exclusion criteria: * adult patient under guardianship * patient under judicial protection * it proves impossible to correctly inform the patient * birth occurring before 34 weeks of pregnancy * birth not resulting in 2 living children

Keywords: cesarean section vaginal birth twins urinary incontinence sexuality quality of life
superobese patients

Conditions: Obesity

Summary: super obesity (so) is defined as a body mass index (bmi) \> 50 kg/m2, and represents the extreme severity of the disease, resulting in an increase in morbidity, mortality, and in poorer quality of life compared with morbid obesity (bmi \> 35 and \<50 kg/m2).


Eligibility criteria:
inclusion criteria: * morbid and superobese patients exclusion criteria: * follow up not completed
aggressive fluid hydration for the prevention of post-ercp pancreatitis

Conditions: Pancreatitis

Summary: aggressive hydration with lactated ringer's solution (lrs) has been shown in a preliminary research to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ercp) pancreatitis. this randomized, controlled trial was designed to assess the effect of peri-procedural aggressive intravenous hydration with lrs on the incidence of post ercp pancreatitis.

patients underwent first-time ercp were randomly assigned (1:1) to receive either lrs at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours (aggressive hydration) or lrs at a rate calculated by the holliday-segar method given peri-procedurally as described earlier (standard hydration). visual analog scale, serum amylase, lipase, c-reactive protein (crp), and urine analysis were assessed prior to procedure and 24 hours after. the primary endpoint was post ercp pancreatitis defined as new or increased epigastric pain persisting for ≥24 hours, elevation of amylase or lipase \>3 times the upper limit of normal.

Eligibility criteria:
inclusion criteria: * patients at age between 18-65 years old undergoing first time ercp exclusion criteria: * ongoing acute pancreatitis * chronic pancreaittis * prior sphincterotomy * ongoing hypotension including those with sepsis * cardiac insufficiency (ci, \>nyha class ii heart failure) * renal insufficiency (ri, creatinine clearance \<40ml/min) * severe liver dysfunction (albumin \< 3mg/dl) * respiratory insufficiency (defined as oxygen saturation \< 90%) * pregnancy * hyponatremia (na+ levels \< 130meq/l)) * hypernatremia (na+ levels \> 150meq/l)
a pilot study evaluating the usability of the oabi mobile application

Conditions: Overactive Bladder

Summary: our primary purpose is to assess the use feasibility and acceptability of the study phone app called, "oabi" app with patients diagnosed with overactive bladder disorder (oab).

tracking overactive bladder disorder can be an important part of managing the disease. it can help the patient and the health care providers keep a tab on what is working to help manage oab symptoms. tracking urination patterns can actually help patients normalize their bladder problems. by focusing on certain behaviors and habits that contribute to their oab and changing those behaviors, patients can effectively control oab symptoms. the oabi mobile application has been created with the goal of helping patients learn more about their day-to-day symptoms as well as track and self-manage their symptoms. additionally, the oabi app connects patients with their hcp via a clinician portal to boost communication, and encourage patient-provider interaction. the goal of this pilot study is to evaluate the usability and acceptability of the oabi mobile app.

Eligibility criteria:
inclusion criteria: * patients with a primary diagnosis of oab (with active oab symptoms) with or without urge incontinence who are: * treatment-naive patients who started a new treatment within two weeks prior to the study enrollment * transitioning to another treatment (pharmacotherapy) * transitioning from behavioral therapy to pharmacotherapy * adults aged 18 yrs and above. * own a smartphone with android operating system with an os of 5.0 or higher or willing to use a study phone as their primary for the duration of the study (samsung galaxy s6). * sufficient understanding of the english language to be able to read and understand study procedures. * willing to participate in the research study and sign informed consent. * has adequate access to the internet to use the app. exclusion criteria: * subjects unable or unwilling to participate for at least three months. * subjects with vision, hearing, and/or speech problems that may limit their participation in data collection procedures. * subjects with physical limitations that limit may their ability to use a smartphone, effectively navigate a smartphone app, and type on a smartphone. * participants with the history of urological surgery or those currently using a urinary sling. * participants on botox treatment for oab. * participants with oab symptoms due to coexisting conditions such as urinary tract infection (uti), and or benign prostatic hypertrophy (bph).
evolution of dmdd children and adolescent

Conditions: Disruptive Mood Dysregulation Disorder; Prognosis Factors; Suicidal Behaviors; Actigraphy

Summary: little is known about the natural course and prognosis factors of inpatients and outpatients with disruptive mood dysregulation disorder (dmdd). the investigators conducted a cross-sectional study to determine the evolution of a sample of dmdd patients referred to the hospital for suicidal behaviors between 2013 and 2018 in terms of diagnostic stability, psychiatric comorbidity, and psychosocial factors. a group of patients with various episodic mood disturbances was used as a clinical case control group. in addition to change in dmdd symptoms across time, the investigators examined the onset and persistence of psychiatric comorbidity using the kiddie-sads pl and suicidal behaviors using the colombia suicidality severity rating scale. the investigators also examined the persistence of depressive symptoms using the beck depression inventory (bdi-ii), the persistence of emotional lability (affective lability scale-18), borderline traits (abbreviated diagnostic of inventory borderline). socio-demographic, clinical features and actigraphy-measured sleep characteristics determined between 2013 and 2018 were used to predict the evolution of the dmdd patients and the clinical control group.


Eligibility criteria:
inclusion criteria: * boys and girls between 10 and 25-year-old * patients who had been referred to the university hospital of amiens for suicidal behaviors between 2013 and 2018 * patients who participated to the study "clinical and actigraphy-measured profiles of inpatient youths with suicidal behavior: exploration of the severe mood dysregulation" exclusion criteria: * no affiliation to a social security service * persons deprived of their liberty as stipulated in article l.1121-6 of the public health code

Keywords: disruptive mood dysregulation disorder prognosis factors natural course suicidal behaviors actigraphy pediatric depressive disorder
a double-blind, group-comparison study using zolpidem (myslee) as a comparative drug in patients with insomnia

Conditions: Sleep Initiation and Maintenance Disorders; Sleep Disorders

Summary: the purpose of this study is to investigate the efficacy and safety of fk199b (zolpidem mr tablet) in patients with insomnia by a randomized, double-blind, group-comparison study using zolpidem (myslee) as a comparative drug


Eligibility criteria:
inclusion criteria: * clinical diagnosis of nonorganic insomnia. * must be able to swallow tablets exclusion criteria: * allergic reactions to zolpidem (myslee) * serious cardiac disorders; serious hepatic impairment; serious renal diseases, etc.

Keywords: zolpidem sleep initiation and maintenance disorders hypnotics and sedatives double-blind study comparative study
probiotics improve adult allergic rhinitis and regulate gut microbiota

Conditions: Allergic Rhinitis

Summary: assessing the clinical efficacy of weizmannia coagulans bc99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.


Eligibility criteria:
inclusion criteria: voluntarily and in writing, sign an informed consent form agreeing to participate in this study; able to complete the study as required by the trial protocol; age between 18 and 65 years old; meet the diagnostic criteria for allergic rhinitis established in the "chinese guidelines for the diagnosis and treatment of allergic rhinitis (2022 revised edition)"; symptoms: presence of two or more symptoms such as sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with daily symptoms lasting or accumulating for more than 1 hour, which may be accompanied by eye itching, tearing, and redness of the eyes and other ocular symptoms; signs: pale and edematous nasal mucosa, which may be accompanied by watery secretions.- exclusion criteria: use of drugs affecting the gut microbiota (including antimicrobial agents, probiotics, intestinal mucosal protective agents, traditional chinese patent medicines, etc.) for more than 1 week within 1 month prior to screening; patients with coexisting pulmonary tuberculosis; patients with coexisting allergic asthma; patients with nasal polyps or severe nasal septum deviation; patients with severe systemic diseases or malignant tumors; individuals with congenital genetic diseases or congenital immunodeficiency diseases; regular use of probiotics or prebiotics within 6 months prior to the screening period; patients with severe gastrointestinal diseases (including severe diarrhea, inflammatory bowel diseases, etc.); individuals with metabolic syndrome (including obesity, dyslipidemia, hypertension, diabetes, etc.); patients with sinusitis, otitis media, or respiratory tract infections; individuals allergic to any components of the probiotics used in this trial; pregnant or lactating women or those planning to conceive in the near future; those who discontinue the test sample or take other medications midway, making it impossible to determine efficacy or with incomplete data; recent use of products similar to the test function, affecting the judgment of the results; participants who cannot participate in the trial due to their own reasons; other participants deemed ineligible by the researcher. -
treatment of hidradenitis suppurativa using etanercept

Conditions: Hidradenitis Suppurativa

Summary: therapy with etanercept, a tnf inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of hs.


Eligibility criteria:
inclusion criteria: * chronic hs for \> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with hs * localizes to skin folds including any of axillx, breast, abdomen and groin * active disease * negative pregnancy test within 7 days before the first dose of study drug * sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study exclusion criteria: * concurrent active infection including tuberculosis * concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic immunosuppressants, systemic retinoids or ant-tnf agents * severe comorbidities (diabetes mellitus requiring insulin, q f of any severity, mi, unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary disease, history of cancer \*thin 5_ years except cutaneous basal cell or squamous cell carcinoma or in situ cervical carcinoma, history of tb or tb exposure, chronic hepatitis b or c, sle, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy * currently enrolled or enrolled within 90 days prior in any trial for treatment of hs * known hiv positive * contraindication to etanercept as defined in package insert
psychological impact, mental health and sleep disorder among patients hospitalized and health care workers during the 2019 coronavirus outbreak (covid-19)

Conditions: Covid19

Summary: covid-19 is an infectious disease caused by the last coronavirus discovered, called sars-cov-2. symptoms encountered in covid-19 are: cough, breathing difficulties (dyspnea, chest pain, etc.), pyrexia, anosmia (loss of smell) and/or dysgeusia (loss of taste), but also ent symptoms (rhinitis type, odynophagia), headaches, asthenia, muscle pain, confusion and diarrhea. infection with sars-cov-2 can also be asymptomatic. covid-19 can be passed from person to person by respiratory droplets expelled when a person speaks, coughs or sneezes. the currently estimated incubation period ranges from 1 to 14 days, and most often this is around 5 days. according to a literature review, there is strong evidence that covid-19 has an impact on mental health (anxiety being the most common symptom) whether in the general population, healthcare workers or vulnerable populations. the objective of this project is to assess mental health and sleep disorders within two populations: elderly patients and nursing staff.


Eligibility criteria:
inclusion criteria: * subjects 65 years of age or older, having been hospitalized for covid-19 within the chu brugmann hospital * people aged 18 or over, member of the nursing staff of the chu brugmann hospital, having worked during covid-19. exclusion criteria: * incoherent patients * severe presbycusis * oral expression impairment * insurmountable language barrier
sarcopenia in older patient with prostate cancer, prevalence and incidence after androgen deprivation therapy

Conditions: Prostate Cancer

Summary: prostate cancer is the most common cancer among men 50 years and older and mainly affets patients 75 years old. androgen deprivation therapy is indicatated in intermediates and high risks form of prostate cancer, in association with radiotherapy for 6 monts to 3 years. it is also indicated after surgery. current therapies induce inhibition of sexual hormones as androgens among which testosterone. these therapies present side effects which have to be acknowledeged during the elaboration therapeutic startegies in older patients: hypogonadism induced by androgen deprivation therapy (adt) causes loss of bone mineral density, diminution of lean body mass and increase of fat body mass. sarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. in addition to aging, many factors may contribute to sarcopenia as cancer and/or adt. this cohort study aims to evaluate risk factors associated to sarcopenia prevalence and the relationship between adt and sarcopenia incidence, in patients 70 years or older with localized or locally advanced prostate cancer


Eligibility criteria:
inclusion criteria: * patients aged 70 years and older * proven localized or locally advanced prostate cancer * treated by radiotherapy associated to adt * cga needed (screened by g8 score ≤14) exclusion criteria: * protected pateint under guardiaship * metastatic prostate cancer * patient refusal * patient cripled with severe dementia
the effects of combined spinal epidurals on fever during labor of first-time mothers

Conditions: Vaginal Delivery

Summary: the purpose of this study is to determine if the epidural of local anesthetics has an effect on fever that may occur in first time mothers during labor.

intrapartum fever (fever during labor) is a real and potentially devastating problem. infants delivered at term who have been exposed to the mother having a fever during labor have a \>9 fold increased risk of cerebral palsy. studies have also shown an increased risk of neonatal encephalopathy associated with fever during labor. maternal fever in the absence of infection is associated with a 4 fold increased risk of neonatal hypoxic encephalopathy and 3.4 fold increased risk of unexplained neonatal seizures. the likely role of inflammatory mediators in the process of maternal fever (temperature \>100.4), regardless of etiology, makes it important to further investigational studies in an effort to discover the etiology of intrapartum fever associated with epidural analgesia. if an inflammatory trigger (i.e., the injection of epidural local anesthetics) can be identified or delayed, then the risks of maternal hyperthermia can be minimized and/ or eliminated. the greatest risk of fever with epidural labor analgesia is seen in women having their first child. this is the same population associated with prolonged labor. although intrapartum fever has a very low incidence overall, 11-33% of first-time mothers will eventually develop fever \>100.4 during epidural analgesia. although the degree of rise in temperature occurs very slowly, it has been shown to be significant enough to cause increased neonatal sepsis workup and antibiotic coverage for both the mother and the neonate.

Eligibility criteria:
inclusion criteria: * having first child (nulliparous) * term pregnancy (\> 37 weeks) * vertex presentation * singleton gestation * ability to provide informed consent * request for analgesia for labor pain exclusion criteria: * birth of second or more child (multiparous) * preterm pregnancy (\< 37 weeks) * presentation other than vertex (ie. breech, transverse) * diabetic * admit temperature \> 99.5 * active drug/alcohol dependence * active genital herpes infection * allergy to anesthetics used

Keywords: first-time mother epidural request vaginal childbirth
study on the diagnostic value of multi-omics combined detection for precancerous lesions of crc

Conditions: Colorectal Cancer; Precancerous Lesion; Inflammatory Bowel Diseases

Summary: colorectal cancer (crc) has become one of the most common malignant tumors in the world, and the key to its prevention and control is early detection and treatment. as colorectal adenoma and inflammatory bowel disease (ibd) are the inevitable precursors of most crc, screening for colorectal adenoma and ibd is of great importance for preventing crc. the existing detection methods have high sensitivity for crc, while limited in colorectal adenoma and ibd. therefore, exploring a detection method with high sensitivity for colorectal adenoma and ibd is necessary. this project intends to use methylation detection technology, lactic acid modified omics, proteomics, metagenomics, and other omics technology, through the analysis of differences in feces and histological results in healthy volunteers, patients with non-advanced adenoma, patients with advanced adenomas, patients with ibd, and patients with crc for early screening.


Eligibility criteria:
inclusion criteria: * patients whose age is between 18-75. * patients who have signed informed consent form. exclusion criteria: * patients who have undergone colonic resection or polypectomy. * patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days. * patients with hereditary colorectal cancer syndrome (including familial adenomatous polyposis). * patients with pregnancy, severe chronic cardiopulmonary and renal disease. * patients with failed cecal intubation. * patients with poor bpq necessitated a second bowel preparation. * patients refusing to participate or to provide informed consent

Keywords: multi-omics study adenoma inflammatory bowel disease
long-term immunogenicity after receipt of je vaccine and antibody response and safety to a booster dose

Conditions: Encephalitis, Japanese

Summary: this study aims to understand the persistence of the japanese encephalitis (je) antibody response in previously vaccinated children. the proposed study will enrol bangladeshi children who had previously participated in a lot to lot consistency study (jev05; nct01567865) of je live attenuated sa 14-14-2 vaccine (cd-jev).

study participants previously immunized with cd-jev (clinical trials identifier: nct01567865, jev05) will have serum collected three and four years after initial vaccination to assess long-term immunogenicity. four years after receiving the initial dose of cd-jev, eligible participants will be vaccinated with a second subcutaneous dose of cd-jev to assess the antibody response. participants will be monitored for safety for 28 days following receipt of the booster dose.

Eligibility criteria:
inclusion criteria: * participant in jev05 study (nct01567865) and received one dose of cd-jev. * resides in the matlab or mirpur study area. * at least one parent or guardian willing to provide written informed consent. exclusion criteria: * received a second dose of japanese encephalitis vaccine within the past three years. * received immunoglobulins and/or any blood products within 90 days prior to enrollment. * been diagnosed with a primary or acquired immunodeficiency, including human immunodeficiency virus (hiv) infection within the past three years.

Keywords: japanese encephalitis vaccines flavivirus infections